• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

COVID-19 Vaccine May Be Less Effective in Patients With Myeloma

by | Aug 2, 2021 | Uncategorized

Source: Cure Today articles Fifteen percent of patients with myeloma did not have detectable antibodies two weeks after receiving the COVID-19 vaccine. Read More

FDA Warns Patients With Myeloma About Pepaxto: Drug Increased Death Rates in Clinical Trial

by | Jul 29, 2021 | Uncategorized

Source: Cure Today articles Patients with myeloma who are receiving Pepaxto should discuss the potential risks and benefits of continued treatment with the drug. Read More

FDA issues alert about mortality risk with Pepaxto for multiple myeloma

by | Jul 28, 2021 | Uncategorized

Source: Healio News The FDA alerted health care providers and patients about clinical trial results that showed increased mortality risk among patients with multiple myeloma treated with melphalan flufenamide.The FDA in February granted accelerated approval to...

Top in hem/onc: Alcohol-related cancer, FDA approval of multiple myeloma therapy

by | Jul 22, 2021 | Uncategorized

Source: Healio News Heavy alcohol consumption contributed to a high number of cancer cases in 2020, according to data in The Lancet Oncology. However, moderate drinking contributed to nearly 1 in 7 alcohol-associated malignancies.A report on the data was the top story...

FDA approves Darzalex Faspro for use in relapsed multiple myeloma

by | Jul 12, 2021 | Uncategorized

Source: Healio News The FDA approved daratumumab and hyaluronidase-fihj for use in combination with pomalidomide and dexamethasone for treatment of patients with relapsed multiple myeloma, including those refractory to lenalidomide.Daratumumab and hyaluronidase-fihj...

FDA Approves Darzalex Faspro for Second-Line Treatment of Multiple Myeloma

by | Jul 12, 2021 | Uncategorized

Source: Cure Today articles Darzalex Faspro has received FDA approval for use in combination with pomalidomide and dexamethasone for patients with multiple myeloma who previously received one line of therapy. Read More
« Older Entries
Next Entries »

Recent Content

  • A systematic epidemiological trends analysis study in global burden of multiple myeloma and 29 years forecast
  • Talquetamab and Teclistamab Achieve Deep, Durable Responses in Patients With Relapsed, Refractory Multiple Myeloma
  • Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study
  • Fixed-Dose Subcutaneous Sarclisa Combo is Non-Inferior to IV Sarclisa in R/R Myeloma
  • Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma
  • Tunneling nanotubes between bone marrow stromal cells support transmitophagy and resistance to apoptosis in myeloma
  • IVIG Supplementation Reduces Infection Risk in Patients With Multiple Myeloma Receiving Teclistamab
  • Combination induces durable responses in advanced multiple myeloma
  • Patient-reported outcome domains in multiple myeloma randomized controlled trials and association with survival outcomes
  • Peroxiredoxin 6 maintains mitochondrial homeostasis and promotes tumor progression through ROS/JNK/p38 MAPK signaling pathway in multiple myeloma
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT